Years after accelerated approval debacle, FDA panel backs Pfizer's Mylotarg
admin 11th July 2017 Uncategorised 0Seven years after the FDA pushed Pfizer’s Mylotarg off the market for flunking a confirmatory trial, it’s in line for a return. The acute myeloid leukemia drug won backing for a new FDA approval Tuesday after Pfizer put up new data.
More: Years after accelerated approval debacle, FDA panel backs Pfizer's Mylotarg
Source: fierce